EAM
QTTB icon

Exome Asset Management’s Q32 Bio QTTB Stock Holding History

Exome Asset Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-43,865
Closed -$787K – 82
2024
Q2 		$787K Sell
43,865
-21,156
-33% -$506K 0.7% 42
2024
Q1 		$1.11M Buy
+65,021
New +$896K 0.95% 44

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Exome Asset Management's QTTB Position: Q3 2024 in Review

Exome Asset Management sold out of Q32 Bio (QTTB) in Q3 2024, closing a stake of 43,865 shares — an estimated $787K sold.

Exome Asset Management first reported a position in QTTB in Q1 2024 and held it in 2 quarters. The position peaked at $1.11M in Q1 2024. 73 funds tracked by Wall St. Rank hold QTTB as of Q3 2024.

  • Exome Asset Management reported no remaining Q32 Bio position as of Q3 2024 after selling out during the quarter.
  • Exome Asset Management sold 43,865 Q32 Bio shares in Q3 2024, an estimated $787K.
  • Exome Asset Management first reported a position in Q32 Bio in Q1 2024 and held it in 2 quarters.
  • Exome Asset Management's Q32 Bio position peaked at $1.11M in Q1 2024.
  • 73 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2024.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.